Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern

Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, Mariana Ruiz Silva, View ORCID ProfileGregory Walker, Andrea Kidinger, Thomas Angelovich, Emily Waring, Supavadee Amatayakul-Chantler, Nathan Roth, Germano Coppola, Malinna Yeang, Tyra Jean, View ORCID ProfileCharles Foster, Alexandra Carey Hoppe, C. Mee Ling Munier, David Darley, Melissa Churchill, Damian Starck, Daniel Christ, Gail Matthews, View ORCID ProfileWilliam Rawlinson, Anthony D. Kelleher, Stuart Turville
doi: https://doi.org/10.1101/2022.07.07.22277128
Anupriya Aggarwal
1The Kirby Institute, University of New South Wales, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anouschka Akerman
1The Kirby Institute, University of New South Wales, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vanessa Milogiannakis
1The Kirby Institute, University of New South Wales, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Ruiz Silva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Walker
2Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gregory Walker
Andrea Kidinger
1The Kirby Institute, University of New South Wales, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Angelovich
3School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily Waring
3School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Supavadee Amatayakul-Chantler
4Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan Roth
4Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Germano Coppola
4Department of Bioanalytical Sciences, Plasma Product Development, Research & Development, CSL Behring AG, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malinna Yeang
2Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tyra Jean
2Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Foster
2Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charles Foster
Alexandra Carey Hoppe
1The Kirby Institute, University of New South Wales, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Mee Ling Munier
1The Kirby Institute, University of New South Wales, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Darley
5St Vincent’s Hospital, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa Churchill
3School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Damian Starck
6Molecular Diagnostic Medicine Laboratory, Sydpath, St Vincent’s Hospital, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Christ
7Garvan Institute of Medical Research, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gail Matthews
1The Kirby Institute, University of New South Wales, New South Wales, Australia
5St Vincent’s Hospital, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Rawlinson
2Serology and Virology Division (SAViD), NSW Health Pathology, Randwick, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for William Rawlinson
Anthony D. Kelleher
1The Kirby Institute, University of New South Wales, New South Wales, Australia
5St Vincent’s Hospital, Sydney, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stuart Turville
1The Kirby Institute, University of New South Wales, New South Wales, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sturville@kirby.unsw.edu.au
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Genetically distinct viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been recorded since January 2020. Over this time global vaccine programs have been introduced, contributing to lower COVID-19 hospitalisation and mortality rates, particularly in developed countries. In late 2021, the Omicron BA.1 variant emerged, with substantially different genetic differences and clinical effects from other variants of concern (VOC). This variant demonstrated higher numbers of polymorphisms in the gene encoding the Spike (S) protein, and it has displaced the previously dominant Delta variant. Shortly after dominating global spread in early 2022, BA.1 was supplanted by the genetically distinct Omicron lineage BA.2. A sub-lineage of BA.2, designated BA.5 has now started to dominate globally, with the potential to supplant BA.2. To address the relative threat of BA.5, we determined infectivity to particle ratios in primary nasopharyngeal samples and expanded low passage isolates in a well characterised, genetically engineered ACE2/TMPRSS2 cell line. We then assessed the impact of BA.5 infection on humoral neutralisation in vitro, in vaccinated and convalescent cohorts, using concentrated human IgG pooled from thousands of plasma donors, and licensed monoclonal antibody therapies. The infectivity of virus in primary swabs and expanded isolates revealed that whilst BA.1 and BA.2 are attenuated through ACE2/TMPRSS2, BA.5 infectivity is equivalent to that of an early 2020 circulating clade and has greater sensitivity to the TMPRSS2 inhibitor Nafamostat. As with BA.1, we observed BA.5 to significantly reduce neutralisation titres across all donors. Concentrated pooled human IgG from convalescent and vaccinated donors had greater breadth of neutralisation, although the potency was still reduced 7-fold with BA.5. Of all therapeutic antibodies tested, we observed a 14.3-fold reduction using Evusheld and 16.8-fold reduction using Sotrovimab when neutralising a Clade A versus BA.5 isolate. These results have implications for ongoing tracking and management of Omicron waves globally.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

MRF2005760/Department of Health | National Health and Medical Research Council (NHMRC) MRF2001684/Department of Health | National Health and Medical Research Council (NHMRC) Covid Rd 2 Grant/NSW Ministry of Health (NSW Health)

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All human serum samples were obtained with written informed consent from the participants (2020/ETH00964; 2020/ETH02068) and are approved through the St Vincents Hospital Sydney NSW Ethics committee

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors. Upon publication we will provide data through Figshare

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted July 10, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, Mariana Ruiz Silva, Gregory Walker, Andrea Kidinger, Thomas Angelovich, Emily Waring, Supavadee Amatayakul-Chantler, Nathan Roth, Germano Coppola, Malinna Yeang, Tyra Jean, Charles Foster, Alexandra Carey Hoppe, C. Mee Ling Munier, David Darley, Melissa Churchill, Damian Starck, Daniel Christ, Gail Matthews, William Rawlinson, Anthony D. Kelleher, Stuart Turville
medRxiv 2022.07.07.22277128; doi: https://doi.org/10.1101/2022.07.07.22277128
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Anupriya Aggarwal, Anouschka Akerman, Vanessa Milogiannakis, Mariana Ruiz Silva, Gregory Walker, Andrea Kidinger, Thomas Angelovich, Emily Waring, Supavadee Amatayakul-Chantler, Nathan Roth, Germano Coppola, Malinna Yeang, Tyra Jean, Charles Foster, Alexandra Carey Hoppe, C. Mee Ling Munier, David Darley, Melissa Churchill, Damian Starck, Daniel Christ, Gail Matthews, William Rawlinson, Anthony D. Kelleher, Stuart Turville
medRxiv 2022.07.07.22277128; doi: https://doi.org/10.1101/2022.07.07.22277128

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (179)
  • Allergy and Immunology (434)
  • Anesthesia (99)
  • Cardiovascular Medicine (948)
  • Dentistry and Oral Medicine (178)
  • Dermatology (110)
  • Emergency Medicine (260)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (422)
  • Epidemiology (8989)
  • Forensic Medicine (4)
  • Gastroenterology (420)
  • Genetic and Genomic Medicine (1959)
  • Geriatric Medicine (190)
  • Health Economics (402)
  • Health Informatics (1329)
  • Health Policy (660)
  • Health Systems and Quality Improvement (519)
  • Hematology (212)
  • HIV/AIDS (420)
  • Infectious Diseases (except HIV/AIDS) (10809)
  • Intensive Care and Critical Care Medicine (575)
  • Medical Education (200)
  • Medical Ethics (54)
  • Nephrology (222)
  • Neurology (1830)
  • Nursing (110)
  • Nutrition (274)
  • Obstetrics and Gynecology (353)
  • Occupational and Environmental Health (470)
  • Oncology (999)
  • Ophthalmology (298)
  • Orthopedics (111)
  • Otolaryngology (182)
  • Pain Medicine (126)
  • Palliative Medicine (44)
  • Pathology (265)
  • Pediatrics (580)
  • Pharmacology and Therapeutics (276)
  • Primary Care Research (234)
  • Psychiatry and Clinical Psychology (1904)
  • Public and Global Health (4123)
  • Radiology and Imaging (676)
  • Rehabilitation Medicine and Physical Therapy (368)
  • Respiratory Medicine (549)
  • Rheumatology (225)
  • Sexual and Reproductive Health (191)
  • Sports Medicine (177)
  • Surgery (207)
  • Toxicology (39)
  • Transplantation (109)
  • Urology (81)